Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.47 |
| ▸ | PDE4A | P27815 | 12/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027109 | 0.85 | CASP1 (0.47) | CASP1HSD17B10PDE4BPDE4APDE4C | |
| SCHEMBL6231255 | 0.83 | CASP1 (0.55) | CASP1HSD17B10PDE4BPDE4APDE4C | |
| SCHEMBL6826307 | 0.82 | CASP1 (0.54) | CASP1HSD17B10PDE4BPDE4APDE4C | |
| SCHEMBL6815488 | 0.82 | CASP1 (0.54) | CASP1HSD17B10PDE4BPDE4APDE4C | |
| SCHEMBL6826506 | 0.81 | CASP1 (0.50) | CASP1HSD17B10PDE4BPDE4APDE4C | |
| SCHEMBL5703639 | 0.81 | PDE4B (0.50) | CASP1HSD17B10PDE4BPDE4APDE4C | |
| SCHEMBL5498111 | 0.80 | CASP1 (0.49) | CASP1HSD17B10PDE4BPDE4APDE4C | |
| SCHEMBL7355456 | 0.80 | PDE4A (0.51) | PDE4BPDE4APDE4CPDE4DPDE5A | |
| SCHEMBL8357874 | 0.79 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DPOLB | |
| SCHEMBL9269715 | 0.78 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649095-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| US-7649095-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| EP-1308440-B1 | PIPERIDINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-1308440-B1 | PIPERIDINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-7109342-B2 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189656-A1 | Piperidine derivatives and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-08-24 | — | — | US | disclosed |
| US-20040044036-A1 | Piperidine derivatives and drugs containing these derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1308440-A1 | PIPERIDINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044036-A1 | Piperidine derivatives and drugs containing these derivatives as active ingredient | PDE4A, PDE4B, PDE4D | CASP1 220/4885HSD17B10 3690/4885PDE4B 2/4885 |
| US-20060189656-A1 | Piperidine derivatives and agent comprising the derivative as active ingredient | PDE4A, PDE4B, PDE4D | CASP1 272/4885HSD17B10 3959/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.